Published in Antimicrob Agents Chemother on January 20, 2015
Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. Antimicrob Agents Chemother (2015) 0.91
A complex game of hide and seek: the search for new antifungals. Medchemcomm (2016) 0.82
Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi. Antimicrob Agents Chemother (2015) 0.78
Fungal CYP51 Inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds. Antimicrob Agents Chemother (2016) 0.76
VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection. Antimicrob Agents Chemother (2015) 0.75
Efficacy of the Investigational Antifungal VT-1161 in Treating Naturally Occurring Coccidioidomycosis in Dogs. Antimicrob Agents Chemother (2017) 0.75
The Tetrazole VT-1161 Is a Potent Inhibitor of Trichophyton rubrum through its Inhibition of T. rubrum CYP51. Antimicrob Agents Chemother (2017) 0.75
Epidemiological trends in skin mycoses worldwide. Mycoses (2008) 2.79
How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data. Arch Dermatol (1998) 2.45
The clinical pharmacokinetics of itraconazole: an overview. Mycoses (1989) 2.27
Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev (1998) 2.21
Updates on the epidemiology of dermatophyte infections. Mycopathologia (2008) 2.05
Epidemiology of superficial fungal infections. Clin Dermatol (2010) 1.52
History of the development of azole derivatives. Clin Microbiol Infect (2004) 1.45
Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol (1998) 1.45
Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Antimicrob Agents Chemother (1995) 1.39
Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. Clin Microbiol Infect (2009) 1.22
Design and optimization of highly-selective fungal CYP51 inhibitors. Bioorg Med Chem Lett (2014) 1.14
Epidemiology of dermatophytoses: retrospective analysis from 2005 to 2010 and comparison with previous data from 1975. New Microbiol (2012) 1.13
Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am (2006) 1.13
The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother (2014) 1.13
Cutaneous fungal infections in the United States: Analysis of the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS), 1995-2004. Int J Dermatol (2009) 0.98
Hepatotoxicity induced by antifungal drugs itraconazole and fluconazole in rats: a comparative in vivo study. Hum Exp Toxicol (2004) 0.93
The nail in the elderly. Clin Dermatol (2010) 0.91
Patient satisfaction with oral versus nonoral therapeutic approaches in onychomycosis. J Am Podiatr Med Assoc (2001) 0.90
Intracutaneous distributions of fluconazole, itraconazole, and griseofulvin in Guinea pigs and binding to human stratum corneum. Antimicrob Agents Chemother (2004) 0.89
Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta-analysis of efficacy for continuous and intermittent regimens. J Eur Acad Dermatol Venereol (2012) 0.87
Evaluation of antifungal efficacy in an optimized animal model of Trichophyton mentagrophytes-dermatophytosis. J Chemother (2004) 0.87
Serious adverse events reporting on systemic terbinafine: a Danish register-based study. Acta Derm Venereol (2011) 0.84
Drug-induced heart failure. Am J Health Syst Pharm (2011) 0.82
A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol (2011) 0.81
Systematic review of severe acute liver injury caused by terbinafine. Int J Clin Pharm (2014) 0.80
Antifungal PK/PD considerations in fungal pulmonary infections. Semin Respir Crit Care Med (2011) 0.79
A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol Venereol (2005) 0.78
Therapies for the treatment of onychomycosis. Clin Dermatol (2013) 0.78
A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. J Am Acad Dermatol (2013) 0.77
Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol (1997) 0.77
The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother (2014) 1.13
Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. Antimicrob Agents Chemother (2015) 0.91
Ability of hydroxypropyl chitosan nail lacquer to protect against dermatophyte nail infection. Antimicrob Agents Chemother (2014) 0.90
Fungal CYP51 Inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds. Antimicrob Agents Chemother (2016) 0.76